Astal Laboratories
- Market cap
- ₹ 281 Cr.
- P/E
- 19.6x
- P/B
- 0.86x
- 52-week range
- 60.45 – 100.9
- ROE
- 8%
- ROCE
- 9%
- Dividend yield
- 0%
- Debt / equity
- 0.15
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Astal Laboratories Limited is an India-based company, which is engaged in the manufacturing and sale of pharmaceutical intermediates and bulk drugs. The Company is engaged in manufacturing fine chemicals, specialty chemicals and pharmaceutical intermediates. The Company’s products include HF Acid (2-Chloro-1,3-Bis (Dimethylamino) Trimethinium Hexafluorophosphate); 4-Methyl Sulphonyl Phenyl Acetic acid, (1R,3R)-methyl 1-(benzo[d][1,3] dioxol-5-yl)- 2,3,4,9-tetrahydro-1 H-pyrido[3,4-b]indole-3- carboxylate hydrochloride; L-Valine methyl ester Hydrochloride (LVMH); L-Valine benzyl ester Hydrochloride; N-[(2-Cyanobiphenyl-4-methyl)- L-Valine methyl ester Hydrochloride; D-Tryptophan Methyl Ester Hydrochloride; Moc-L-valine (N-(Methoxycarbonyl)-L-valine); 2-Ethoxyethyl-4-methylbenzene sulfonate; 2 Piperidin-4-yl-1H-benzoimidazole; Alpha, alpha-Dimethyl Phenyl Acetic Acid (2-Methyl-2-phenylpropionic acid); 2-(4-bromophenyl)-2-methylpropionic acid; Methyl 2,2-dimethylphenylacetate, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Astal Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.6 against a typical 34.6: cheaper than most peers (1st = cheapest).56th of 220
- Share price, 3 months−22.6% against a typical −0.5%.186th of 200
- Size₹ 281.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).110th of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 23 | 52 | 134 | 101 |
| Expenses | 19 | 49 | 124 | 89 |
| Operating Profit | 4 | 4 | 10 | 12 |
| OPM % | 17.8% | 6.8% | 7.6% | 12.1% |
| Other Income | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 |
| Profit before tax | 4 | 3 | 8 | 10 |
| Tax % | 28.6% | 24.5% | 7.9% | 9% |
| Net Profit | 3 | 2 | 8 | 9 |
| EPS in Rs | 2.79 | 2.19 | 1.82 | 2.15 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 288%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 65%
- 10 Years
- 13%
- 5 Years
- 49%
- 3 Years
- 44%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Astal Laboratories | ₹ 64.10 | ₹ 281 Cr. | 19.6x | 0.9x | 8% | — |
| Bajaj Finance | ₹ 927.00 | ₹ 5,77,146 Cr. | 27x | 6.2x | — | 24.2% |
| Shriram Finance | ₹ 867.00 | ₹ 2,04,004 Cr. | 14x | 3x | — | 22.8% |
| Jio Financial Services | ₹ 205.00 | ₹ 1,35,364 Cr. | 100.8x | 1.2x | — | 49.8% |
| Tata Capital | ₹ 307.05 | ₹ 1,30,358 Cr. | 30.8x | 3.4x | — | 17.2% |
| Power Finance Corporation | ₹ 316.00 | ₹ 1,04,283 Cr. | 5.7x | 1.1x | 20.7% | 29.1% |
Management
- Balayogiswara Rao Peddinti
- Chief Financial Officer
- Mahendra Kumar
- Compliance Officer, Company Secretary
- Sudheer Karna Kankanala
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.